Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Compare daily and long-term volatility across major coins to inform allocation and risk controls in your portfolio.
20,930 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
A rally powered by a small group of tech stocks is raising concerns about the durability of trump’s bull market stand...
A fresh analysis finds the study: bipartisan social security plan to borrow and invest funds would leave taxpayers wi...
Stifel boosted CrowdStrike’s target to $660 ahead of the June earnings release, signaling renewed optimism on growth ...
With mortgage rates persisting at elevated levels, lenders are testing fresh ways to keep homebuyers in the market. A...
In a year of volatile rates, Vanguard’s cheapest short-term bond ETF stands out for ultra-low fees and solid near-ter...
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
Oceaneering International has staged a striking rally, with a fund-backed bet signaling confidence in continued growt...
Analysts weigh the implications of a hypothetical kevin warsh sworn federal chair scenario. Markets could reprice pol...
If you're weighing two ad-tech stocks, this guide breaks down how to think about should zeta global stock versus AppL...
A renewed bond market selloff is sharpening focus on fiscal risks. Analysts say the u.s. debt ‘elephant room’ could q...
New to investing? Learn four practical ETF strategies that help you diversify, automate contributions, manage taxes, ...